Abstract
STUDY OBJECTIVE--The aim was to determine if a new controlled release formulation (Oscorel) of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen has been preferentially prescribed in patients with prior history of gastro-intestinal disturbances. DESIGN--The study was a pharmacy records based comparison of the rates of prior prescribing of drugs indicated for peptic ulcer treatment in first recipients of Oscorel in 1989 versus recipients of other NSAID products. SETTING--A representative panel of Dutch community pharmacies serving approximately 425,000 people was used. MAIN RESULTS--Oscorel was launched in January 1989. Data on prescriptions dispensed in 1987-1988 to a total of 837 first users of Oscorel were analysed and compared with the dispensing history of a reference population including 30,787 patients who did not receive a prescription for Oscorel during 1989. Compared to the reference population, first users of Oscorel included a greater proportion of females, of patients 75 years and older, of heavy users of NSAIDs, and of patients switching among different NSAIDs. A total of 24.1% of first users of Oscorel had received peptic ulcer therapy in 1987-1988, versus 15.7% of the reference population. The rate ratio was 1.54, with 95% confidence interval of 1.36-1.74. Adjustment for stratifying variables caused only minor changes in the rate ratio, which remained stable on 1.5. CONCLUSIONS--Oscorel appears to have been channelled into use in patients with recognised risk factors for gastrointestinal toxicity. This preferential prescribing probably resulted from expectations and claims that this product has a lower risk of such toxicity.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carson J. L., Strom B. L., Morse M. L., West S. L., Soper K. A., Stolley P. D., Jones J. K. The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1987 Jun;147(6):1054–1059. [PubMed] [Google Scholar]
- Epstein A. M., Read J. L., Winickoff R. Physician beliefs, attitudes, and prescribing behavior for anti-inflammatory drugs. Am J Med. 1984 Aug;77(2):313–318. doi: 10.1016/0002-9343(84)90709-5. [DOI] [PubMed] [Google Scholar]
- Hawkey C. J. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ. 1990 Feb 3;300(6720):278–284. doi: 10.1136/bmj.300.6720.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hernandez Avila M., Walker A. M., Romieu I., Spiegelman D. L., Perera D. R., Jick H. Choice of non-steroidal anti-inflammatory drug in persons treated for dyspepsia. Lancet. 1988 Sep 3;2(8610):556–559. doi: 10.1016/s0140-6736(88)92670-0. [DOI] [PubMed] [Google Scholar]
- Jick S. S., Perera D. R., Walker A. M., Jick H. Non-steroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. Lancet. 1987 Aug 15;2(8555):380–382. doi: 10.1016/s0140-6736(87)92393-2. [DOI] [PubMed] [Google Scholar]
- Rossi A. C., Hsu J. P., Faich G. A. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. Br Med J (Clin Res Ed) 1987 Jan 17;294(6565):147–150. doi: 10.1136/bmj.294.6565.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Strom B. L., Taragin M. I., Carson J. L. Gastrointestinal bleeding from the nonsteroidal anti-inflammatory drugs. Agents Actions Suppl. 1990;29:27–38. doi: 10.1007/978-3-0348-7292-8_4. [DOI] [PubMed] [Google Scholar]
- Urquhart J. Two cheers for NSAIDs. Gut. 1986 Nov;27(11):1287–1291. doi: 10.1136/gut.27.11.1287. [DOI] [PMC free article] [PubMed] [Google Scholar]